tradingkey.logo

Eli Lilly and Co

LLY
View Detailed Chart
1010.310USD
-4.730-0.47%
Close 12/05, 16:00ETQuotes delayed by 15 min
955.59BMarket Cap
51.90P/E TTM

Eli Lilly and Co

1010.310
-4.730-0.47%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.47%

5 Days

-6.06%

1 Month

+9.30%

6 Months

+31.23%

Year to Date

+30.87%

1 Year

+22.21%

View Detailed Chart

TradingKey Stock Score of Eli Lilly and Co

Currency: USD Updated: 2025-12-05

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Eli Lilly and Co's Score

Industry at a Glance

Industry Ranking
37 / 159
Overall Ranking
108 / 4582
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 33 analysts
Buy
Current Rating
1047.402
Target Price
+3.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Eli Lilly and Co Highlights

StrengthsRisks

Eli Lilly and Company, commonly referred to as Lilly, is an American multinational pharmaceutical corporation based in Indianapolis, Indiana, with offices in 18 countries and products available in approximately 125 nations. Founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran from the American Civil War, the company carries his name.

As of October 2024, Lilly has achieved the status of the most valuable drug company in the world, boasting a market capitalization of $842 billion, marking the highest valuation ever recorded for a pharmaceutical company. The firm ranks 127th on the Fortune 500, reporting revenues of $34.12 billion. Additionally, it is positioned 221st on the Forbes Global 2000 list, which encompasses the largest publicly traded companies globally, and 252nd on Forbes' list of "America's Best Employers."

Lilly is recognized for its antidepressant medications, including Prozac and Cymbalta, as well as the antipsychotic drug Zyprexa. Its primary revenue sources are the diabetes treatments Humalog and Trulicity.

The company was a pioneer in mass-producing both the polio vaccine, created in 1955 by Jonas Salk, and insulin. Lilly was among the first in the pharmaceutical sector to manufacture human insulin using recombinant DNA technology, producing products like Humulin, Humalog, and the first approved biosimilar insulin in the U.S., known as Basaglar. Additionally, Lilly introduced exenatide to the market as the first of the GLP-1 receptor agonists, followed by highly successful medications in this category, such as Mounjaro and Zepbound.

By 1997, Lilly had become both the largest corporation and the largest philanthropic benefactor in Indiana. In 2009, it pleaded guilty to illegally marketing Zyprexa and agreed to a substantial $1.415 billion settlement, which included a criminal fine of $515 million, making it the largest ever in a healthcare-related case and the highest criminal fine levied against a single corporation in a U.S. criminal prosecution at that time.

Lilly is a full member of the Pharmaceutical Research and Manufacturers of America, as well as the European Federation of Pharmaceutical Industries and Associations.

High Growth
The company's revenue has grown steadily over the past 3 years, averaging 57.82% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 45.04B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 45.87%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 45.87%.
Undervalued
The company’s latest PE is 49.30, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 789.85M shares, decreasing 0.81% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 25.13K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.87.

Eli Lilly and Co News

Eli Lilly $1 trln value is bet on Coke-like future

DUBLIN, Dec 4 (Reuters Breakingviews) - Eli Lilly LLY.N is looking more like a tech giant than a drugmaker. Last month, the creator of Mounjaro and Zepbound’s market value soared past $1 trillion. The U.S. group’s obesity treatments and pipeline of drugs only partly explain the he...

ReutersThu, Dec 4
DUBLIN, Dec 4 (Reuters Breakingviews) - Eli Lilly LLY.N is looking more like a tech giant than a drugmaker. Last month, the creator of Mounjaro and Zepbound’s market value soared past $1 trillion. The U.S. group’s obesity treatments and pipeline of drugs only partly explain the he...

Eli Lilly vs. Novo Nordisk: Why Lilly Is Better Positioned Under Trump's Drug Pricing Pressure

TradingKey - Eli Lilly and Novo Nordisk, the two dominant players in the US weight-loss drug market, are experiencing vastly different investor sentiment despite facing unprecedented GLP-1 drug price cuts under the Trump administration's price cut initiative.

TradingKeyWed, Nov 12
TradingKey - Eli Lilly and Novo Nordisk, the two dominant players in the US weight-loss drug market, are experiencing vastly different investor sentiment despite facing unprecedented GLP-1 drug price cuts under the Trump administration's price cut initiative.

“Trump’s Pharmacy” Cutting Weight-Loss Drug Prices — What This Means for Novo and Lilly

TradingKey - Following agreements with Pfizer and AstraZeneca, the so-called “twin giants” of weight-loss drugs — Novo Nordisk and Eli Lilly — have now also reached pricing deals with the Trump administration. This marks the latest move in Trump’s broader push to cut U.S. drug prices by up to 90%

TradingKeyFri, Nov 7
TradingKey - Following agreements with Pfizer and AstraZeneca, the so-called “twin giants” of weight-loss drugs — Novo Nordisk and Eli Lilly — have now also reached pricing deals with the Trump administration. This marks the latest move in Trump’s broader push to cut U.S. drug prices by up to 90%

Novo Nordisk, Lilly strike deal with Trump to slash weight-loss drug prices

WASHINGTON, Nov 6 (Reuters) - U.S. President Donald Trump, Eli Lilly LLY.N and Novo Nordisk NOVOb.CO unveiled a deal on Thursday to slash the prices of popular GLP-1 weight‑loss drugs for the government's Medicare and Medicaid programs, as well as for cash payers.

ReutersFri, Nov 7
WASHINGTON, Nov 6 (Reuters) - U.S. President Donald Trump, Eli Lilly LLY.N and Novo Nordisk NOVOb.CO unveiled a deal on Thursday to slash the prices of popular GLP-1 weight‑loss drugs for the government's Medicare and Medicaid programs, as well as for cash payers.

Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, source says

Nov 4 (Reuters) - Eli Lilly LLY.N and Novo Nordisk NOVOb.CO are expected to announce deals with the Trump administration to cut prices of their weight-loss drugs in exchange for Medicare coverage, a White House source told Reuters on Tuesday.Patients in the U.S. currently pay the most for prescripti

ReutersWed, Nov 5
Nov 4 (Reuters) - Eli Lilly LLY.N and Novo Nordisk NOVOb.CO are expected to announce deals with the Trump administration to cut prices of their weight-loss drugs in exchange for Medicare coverage, a White House source told Reuters on Tuesday.Patients in the U.S. currently pay the most for prescripti

Novo Nordisk Q3 Earnings Preview: New CEO, Board Overhaul — Can the U.S. Weight-Loss Market Turn Around?

TradingKey - Novo Nordisk (NVO), one of Europe’s pharmaceutical giants and a leader in the weight-loss drug race, will report its Q3 2025 earnings before market open on November 5. Wall Street expects a modest rebound from Q2’s worst growth in four years, but significant pressure on profits remains.

TradingKeyTue, Nov 4
TradingKey - Novo Nordisk (NVO), one of Europe’s pharmaceutical giants and a leader in the weight-loss drug race, will report its Q3 2025 earnings before market open on November 5. Wall Street expects a modest rebound from Q2’s worst growth in four years, but significant pressure on profits remains.

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Eli Lilly and Co Info

Eli Lilly and Company, commonly referred to as Lilly, is an American multinational pharmaceutical corporation based in Indianapolis, Indiana, with offices in 18 countries and products available in approximately 125 nations. Founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran from the American Civil War, the company carries his name.

As of October 2024, Lilly has achieved the status of the most valuable drug company in the world, boasting a market capitalization of $842 billion, marking the highest valuation ever recorded for a pharmaceutical company. The firm ranks 127th on the Fortune 500, reporting revenues of $34.12 billion. Additionally, it is positioned 221st on the Forbes Global 2000 list, which encompasses the largest publicly traded companies globally, and 252nd on Forbes' list of "America's Best Employers."

Lilly is recognized for its antidepressant medications, including Prozac and Cymbalta, as well as the antipsychotic drug Zyprexa. Its primary revenue sources are the diabetes treatments Humalog and Trulicity.

The company was a pioneer in mass-producing both the polio vaccine, created in 1955 by Jonas Salk, and insulin. Lilly was among the first in the pharmaceutical sector to manufacture human insulin using recombinant DNA technology, producing products like Humulin, Humalog, and the first approved biosimilar insulin in the U.S., known as Basaglar. Additionally, Lilly introduced exenatide to the market as the first of the GLP-1 receptor agonists, followed by highly successful medications in this category, such as Mounjaro and Zepbound.

By 1997, Lilly had become both the largest corporation and the largest philanthropic benefactor in Indiana. In 2009, it pleaded guilty to illegally marketing Zyprexa and agreed to a substantial $1.415 billion settlement, which included a criminal fine of $515 million, making it the largest ever in a healthcare-related case and the highest criminal fine levied against a single corporation in a U.S. criminal prosecution at that time.

Lilly is a full member of the Pharmaceutical Research and Manufacturers of America, as well as the European Federation of Pharmaceutical Industries and Associations.

Ticker SymbolLLY
CompanyEli Lilly and Co
CEOMr. David A. (Dave) Ricks
Websitehttps://www.lilly.com/

FAQs

What is the current price of Eli Lilly and Co (LLY)?

The current price of Eli Lilly and Co (LLY) is 1010.310.

What is the symbol of Eli Lilly and Co?

The ticker symbol of Eli Lilly and Co is LLY.

What is the 52-week high of Eli Lilly and Co?

The 52-week high of Eli Lilly and Co is 1111.990.

What is the 52-week low of Eli Lilly and Co?

The 52-week low of Eli Lilly and Co is 623.780.

What is the market capitalization of Eli Lilly and Co?

The market capitalization of Eli Lilly and Co is 955.59B.

What is the net income of Eli Lilly and Co?

The net income of Eli Lilly and Co is 10.59B.

Is Eli Lilly and Co (LLY) currently rated as Buy, Hold, or Sell?

According to analysts, Eli Lilly and Co (LLY) has an overall rating of Buy, with a price target of 1047.402.

What is the Earnings Per Share (EPS TTM) of Eli Lilly and Co (LLY)?

The Earnings Per Share (EPS TTM) of Eli Lilly and Co (LLY) is 20.495.
KeyAI